Atopic dermatitis is a common, chronic, immune-mediated disease associated with 
several comorbidities. Elevated levels of T helper (Th)2, Th22, and also some 
Th1 and Th17 cytokines are found in atopic dermatitis skin lesions. Similar to 
psoriasis, there is a tendency towards increased use of more targeted therapies. 
However, there are still several unmet needs in the treatment of atopic 
dermatitis concerning long-term efficacy, tolerability, safety, route of 
administration, and cost. The increased knowledge of atopic dermatitis 
pathogenesis and the role of Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathways has allowed the development of new compounds 
to inhibit this intracellular signaling pathway implicated in atopic 
dermatitis-related immune responses. Currently, JAK inhibitors are an important 
focus of therapeutic research for atopic dermatitis. Upadacitinib and 
abrocitinib are oral small molecules that inhibit the JAK/STAT pathway by 
selectively blocking JAK1. Data from phase II and III trials are encouraging, 
revealing that JAK1 inhibitors are effective and well-tolerated agents for 
moderate-to-severe atopic dermatitis. Selective JAK1 inhibitors may represent an 
important therapeutic option to be included in the treatment algorithm of atopic 
dermatitis, owing to oral administration and a favorable safety and tolerability 
profile. In this article, we review the current evidence on the efficacy and 
safety of oral selective JAK1 inhibitors for the treatment of atopic dermatitis.